KLRS
NASDAQ
US
Kalaris Therapeutics, Inc. - Common Stock
$5.79
▼ $-0.15
(-2.44%)
Vol 24K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$141.3M
ROE
-76.0%
D/E
0.00
Beta
-0.01
52W
$2–$13
Wall Street Consensus
12 analysts · Apr 20265
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
DTIL
Precision BioSciences Inc
$100.1M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
Earnings
Beat rate: 60.0%
Next Report
May 12, 2026
EPS Estimate: $-0.54
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.54 | — | — |
| Dec 2025 | $-0.54 | $-0.51 | +$0.03 |
| Sep 2025 | $-0.67 | $-0.64 | +$0.03 |
| Jun 2025 | $-0.53 | $-0.61 | $-0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$22.0M | -$10.2M | -$11.3M | -$11.9M | -$10.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -50.0% | -36.6% | -50.0% | -50.0% | -50.0% | -76.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 11.98 | 14.29 | 11.98 | 11.98 | 11.98 | 12.89 |
Key Ratios
ROA (TTM)
-52.3%
EPS (TTM)
$-7.39
52W High
$12.90
52W Low
$2.14
$2.14
52-Week Range
$12.90
Financial Health
Free Cash Flow
-$7.1M
Net Debt
-$96.6M
Cash
$98.1M
Total Debt
$1.4M
As of Dec 31, 2025
How does KLRS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
KLRS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
—
▼
0%
below
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
KLRS profitability vs Biotechnology peers
ROE
-76.0%
▼
13%
below
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-52.3%
▼
12%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
KLRS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
12.9
▲
190%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.0
▼
101%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
KLRS fundamentals radar
KLRS
Peer median
Industry
KLRS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
KLRS vs peers: key metrics
Latest News
No related news yet